5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate has been researched along with veratrine in 1 studies
| Studies (5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate) | Trials (5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate) | Recent Studies (post-2010) (5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate) | Studies (veratrine) | Trials (veratrine) | Recent Studies (post-2010) (veratrine) |
|---|---|---|---|---|---|
| 19 | 0 | 0 | 808 | 1 | 16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Graham, SH; Gwinn, R; Kadota, K; Leach, MJ; Meldrum, BS; Millan, MH; Simon, RP; Swan, JH | 1 |
1 other study(ies) available for 5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate and veratrine
| Article | Year |
|---|---|
Reduction of glutamate release and protection against ischemic brain damage by BW 1003C87.
Topics: Animals; Aspartic Acid; Brain; Caudate Nucleus; Cerebral Arteries; Glutamates; Glutamine; In Vitro Techniques; Ischemic Attack, Transient; Male; Pyrimidines; Rats; Rats, Sprague-Dawley; Taurine; Veratrine | 1992 |